MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
2.880
+0.130
+4.73%
Closed 16:45 12/01 EST
OPEN
2.720
PREV CLOSE
2.750
HIGH
2.910
LOW
2.690
VOLUME
162.23K
TURNOVER
0
52 WEEK HIGH
7.99
52 WEEK LOW
2.250
MARKET CAP
63.49M
P/E (TTM)
-0.8180
1D
5D
1M
3M
1Y
5Y
Delcath Sys: [Amend]General statement of acquisition of beneficial ownership
Press release · 5d ago
Buy Rating Affirmed for Delcath Systems on Strong Commercial Prospects and Novel Treatment Potential
TipRanks · 5d ago
Weekly Report: what happened at DCTH last week (1120-1124)?
Weekly Report · 6d ago
Delcath Sys: Statement of changes in beneficial ownership of securities
Press release · 11/21 17:06
Weekly Report: what happened at DCTH last week (1113-1117)?
Weekly Report · 11/20 11:55
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Delcath's hepzato kit is the only liver directed fda approved treatment for mum, a rare form of cancer. The treatment will launch in the us in january. Delcath has enough cash to get to profitability in 2024. I believe the market is too pessimistic about the growth potential of the company. I have a 3 year price target of $64.5 for the stock.
Seeking Alpha · 11/17 23:40
Delcath Systems: A Promising Investment Due to Upcoming HEPZATO KIT Launch and Strong Future Revenue Projections
H.c. Wainwright maintained a buy rating on delcath systems (dcth) with a price target of $18.00. Swayampakula ramakanth’s buy rating is based on the launch of hepzato kit and the company's potential future revenue.
TipRanks · 11/14 11:29
Marie Thibault of BTIG Maintains Buy Rating for Delcath Systems, Optimistic about HEPZATO Launch and Projected Q1 Revenue
TipRanks · 11/14 02:55
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.